Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Fibromyalgia pain device study pulled before it even started

NCT ID NCT05394610

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if a device called Sana could improve quality of life for people with fibromyalgia, a condition that causes long-term pain. Researchers planned to compare the active device to a sham (fake) device in adults aged 18 to 65 who had fibromyalgia symptoms for at least three years. However, the study was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing to and capable of providing written informed consent prior to the conduct of any study-related procedures. * Male or female, 18 to 65 years of age, inclusive. * Have a history of experiencing fibromyalgia - like symptoms for a minimum of 36 months (3 years) prior to Screening. * Subject must be in good physical health based on physical exams, vitals, and/or self-reporting. For subjects where there may not be sufficient recent medical records to document general good health the participant will be asked to self-report at the investigator's discretion. * Any analgesic medications and medication dosages must be at approximately stable levels for at least 8 weeks prior to enrollment and remain steady throughout the study. * A total score on the Generalized Anxiety Disorder 7-item scale (GAD-7) of 5 or above. * A total score on the Patient Health Questionnaire 8-item (PHQ-8) of 5 or above. * A total score on the STOP-Bang questionnaire of 3 or below. * Willing and able to comply with the study requirements, complete study assessments, and participate at scheduled times for the duration of the Treatment Phase. * Able to understand, speak and read English sufficient for the completion of study assessments. Exclusion Criteria: * Pregnant or lactating females as self-reported. * History or presence of photo-sensitive epilepsy or other photo-sensitive conditions. * History or presence of condition(s) that may affect balance, such as seizure disorders or vertigo. * History of presence of condition (s) that meet the criteria for major depressive disorder (MDD), bipolar disorder, or any other personality disorders, at the discretion of the investigator. * Presence of cancer pain, acute pain following injury or other severe pain not primarily associated with fibromyalgia, at discretion of the investigator. * Surgery or trauma requiring rehabilitation within the last 12 weeks. * Vision impairments that affect perception of light, color, or brightness in one or both eyes, and differences in visual perception between eyes. * Deafness in one or both ears, perceived differences in hearing between ears, or tinnitus. * Current ear or eye infection, untreated allergies, or acute illness that may affect eyes or hearing (e.g., due to congestion). * Presence of inflammation or broken skin around the eyes in the area of the mask. * Presence of narcolepsy or untreated sleep apnea or requiring treatment for sleep apnea such that use of device at bedtime will be interrupted, at discretion of the investigator. * At the discretion of the Investigator, participation in any other clinical study in which medication(s) are being delivered or have used an investigational drug or device within the last 30 days. * Any pending legal action that could prohibit participation or compliance in the study. * Recent history of or current evidence of suicidal ideation or active suicidal behavior, based on medical history, at the discretion of the investigator. * Significant medical conditions or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study or obtaining informed consent, or may prevent the subject from safely participating in study. * Employment by the investigator or the study site, with direct involvement in the proposed study or other studies under the direction of the investigator or study site, or a family member of an employee or of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibromyalgia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.